Snehal Patel, Global Head of Cell Therapy Manufacturing at Bristol Myers Squibb, stand outside the facility on Monday in Bothell. (Andy Bronson / The Herald)

Snehal Patel, Global Head of Cell Therapy Manufacturing at Bristol Myers Squibb, stand outside the facility on Monday in Bothell. (Andy Bronson / The Herald)

Cancer patients nationwide send their blood cells to Bothell

At a Bristol Myers Squibb lab, the cells are altered and returned to patients fighting non-Hodgkin’s lymphoma.

BOTHELL — It might look like an ordinary manufacturing center from the parking lot, but this “factory” is busy producing cancer-fighting cells.

A Bristol Myers Squibb “therapy manufacturing center” in Bothell is ramping up production of a new blood-cancer treatment after it received federal approval earlier this year.

On Feb. 5, the U.S. Food and Drug Administration approved Breyanzi, a cell-based genetic therapy, for commercial use. A one-time infusion, it treats patients with non-Hodgkin’s lymphoma when at least two treatments haven’t worked or have stopped working.

Breyanzi involves re-engineering and revving up a patient’s own immune cells to detect, attack and kill cancer cells.

The 68,000-square-foot Bothell site is equipped to modify T-cells, said Snehal Patel, vice president and global head of cell therapy manufacturing.

Non-Hodgkin’s lymphoma is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. The disorder weakens the immune system and its ability to fight infection. In the U.S., it accounts for about 4% of all cancers. The American Cancer Society estimates that nearly 82,000 people this year will be diagnosed with the non-Hodgkin’s lymphoma.

The personalized therapy begins at one of 40 treatment centers, where a patient’s T-cells, a type of white blood cell, are collected.

The cells are then carefully preserved and shipped to the Bothell site, which serves patients throughout the U.S., Patel said.

At the facility, the cells are genetically altered to locate and destroy cancer cells.

A viral vector — a virus that’s been modified so that it can’t replicate — is used to deliver genetic material to the T-cell. Once it reaches the target, it makes changes to the cell, enabling it to identify and destroy cancer cells. A few weeks later, the enhanced T-cells are returned to the patient in the form of a one-time infusion. Patients are then monitored for several weeks, staying close to the treatment center.

“Breyanzi has deep Pacific Northwest roots from being developed by local scientific teams,” said Ann Lee, senior vice president and head of cell therapy development and operations at Bristol Myers.

Juno Therapeutics, a Bothell biotech firm, began the process in 2013, collaborating with the Fred Hutchinson Cancer Research Center in Seattle, Seattle Children’s Research Institute and Memorial Sloan-Kettering Cancer Center in New York.

Juno was purchased by Celgene Corp in 2018 for $9 billion. A year later, Bristol Myers Squibb acquired Celgene in a $74 billion deal.

The Bristol Meyers Squibb manufacturing center and a separate Canyon Park Business Park location currently employ about 550 people, but the company plans to expand its footprint with the addition of a 44,000-square-foot business center to support employees and enable further manufacturing expansion.

“Travis Lynn and Rian Ziegler — two of our guys — are helping design the new business center,” said Patel, describing it as a “significant investment.”

“We’re proud to invest in the Bothell area,” Patel said “We have employees from Everett, Mill Creek, Monroe and Snohomish. We’ve also recently hired some Boeing folks, giving them the chance to enter the health care space.”

Bristol Myers recently partnered with Shoreline Community College to develop a biotech certification program that prepares students for entry-level laboratory work, Patel said.

Breyanzi is the first of two Bristol Myers cell therapy treatments to receive FDA approval this year for commercial distribution.

In March, the FDA approved Abecma for multiple myeloma, a rare blood cancer that blocks bone marrow from making enough healthy blood cells. The disorder can result in low blood counts that weaken the immune system and damage the bones and kidneys.

Abecma was developed by Celgene and a Boston-based biotech, bluebird bio. It will be produced at a Bristol Myers cell therapy manufacturing site in New Jersey.

Janice Podsada; jpodsada@heraldnet.com; 425-339-3097; Twitter: JanicePods


In consideration of how we voice our opinions in the modern world, we’ve closed comments on our websites. We value the opinions of our readers and we encourage you to keep the conversation going.

Please feel free to share your story tips by emailing editor@bothell-reporter.com.

To share your opinion for publication, submit a letter through our website https://www.bothell-reporter.com/submit-letter/. Include your name, address and daytime phone number. (We’ll only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 300 words or less, we won’t ask you to shorten it.

More in Business

Snehal Patel, Global Head of Cell Therapy Manufacturing at Bristol Myers Squibb, stand outside the facility on Monday, March 29, 2021 in Bothell, Washington. A Bristol Myers Squibb facility in Bothell is one of four facilities in the United States where the company supercharges a person's T-cells to better fight blood cancers. The facility uses a virus  -- a viral delivery system -- to add punch to an individual's T-cells. The T-cells are then returned to the person better-equipped to destroy cancer cells.  (Andy Bronson / The Herald)
Cancer patients nationwide send their blood cells to Bothell

At a Bristol Myers Squibb lab, the cells are altered and returned to patients fighting non-Hodgkin’s lymphoma.

Teaser
First large-scale, human composting facility in the world will open in Auburn

“It’s what nature meant us to do. We just do it faster.”

Whole Foods grocery store entrance (Shutterstock)
King County considers grocery store worker hazard pay for those in unincorporated areas

The King County Metropolitan Council will vote during its next meeting on… Continue reading

Screenshot
WA Democrats consider new tax on billionaires

Plan could raise $5 billion from fewer than 100 taxpayers. Detractors fear it could drive Washington’s wealthiest out of state.

Last summer, people took advantage of the outdoor dining along First Avenue between Gowe and Titus streets in downtown Kent. In Phase 2 of the governor’s reopening plan, which was announced Jan. 28, restaurants can reopen at a maximum 25% capacity and a limit of six people per table. Photo courtesy of Kent Downtown Partnership
Restaurant reprieve: State to relax some indoor restrictions

On Monday, area restaurants and certain entertainment venues may resume indoor service, the governor said.

Stock photo
State Senate passes $1.7 billion in unemployment insurance tax relief

Targets relief to the most affected businesses; helps low-wage workers by raising their benefits

Jason Wilson is a James Beard Award-winning chef and owner of The Lakehouse in Bellevue. Courtesy photo
James Beard Award winner wants to cook with you – virtually

Chef Jason Wilson can give customers an interactive dining experience in their own homes.

2021 Chevrolet Blazer. Courtesy photo
Car review: 2021 Chevrolet Blazer

By Larry Lark, contributor When it comes to certain car models they… Continue reading

2021 Lexus RX 350L. Courtesy photo
Car review: 2021 Lexus RX 350L

By Larry Lark, contributor It’s always a good day when a Lexus… Continue reading

The Cadillac CT4 is designed to appeal to a new generation of Cadillac buyers with its athletic design and astute driving dynamics. Courtesy photo
Car review: 2020 Cadillac CT4 Premium Luxury

By Larry Lark, contributor With apologies to Oldsmobile, “the 2020 CT4 Premium… Continue reading

2021 Mercedes E-350 luxury sedan. Courtesy photo
Car review: 2021 Mercedes E-350 luxury sedan

By Larry Lark, contributor Mercedes-Benz occupies rarified air in the automobile pantheon.… Continue reading